{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/obsessive-compulsive-disorder/supporting-evidence/ssris-in-adults/","result":{"pageContext":{"chapter":{"id":"73a36a4c-8f66-5d63-a4ad-c1667bd42f3b","slug":"ssris-in-adults","fullItemName":"SSRIs in adults","depth":2,"htmlHeader":"<!-- begin field c821f474-be09-475a-8428-8dc3734845a6 --><h2>Evidence on SSRIs in adults</h2><!-- end field c821f474-be09-475a-8428-8dc3734845a6 -->","summary":null,"htmlStringContent":"<!-- begin item e4873610-d04e-499c-85c8-d95dee5babe9 --><!-- begin field 0c8be71b-97bb-4133-bb7b-35ce26468a92 --><p><strong>There is evidence from two systematic reviews (10 and 17 randomized controlled trials [RCTs]; 1629 and 3097 participants; not including escitalopram) that selective serotonin reuptake inhibitors (SSRIs) as a group are superior in efficacy to placebo, but are associated with more (relatively tolerable) adverse effects </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Soomro et al, 2008</a>]<strong>. There is evidence from one RCT (n = 228) that a newer SSRI, escitalopram (at a dose of 20 mg daily), is also superior in efficacy to placebo. There is evidence from a systematic review (eight RCTs; n = 1019) that SSRIs are equal in efficacy to clomipramine, but are better tolerated. The evidence is inconclusive with regard to any one SSRI being superior in efficacy or tolerability to another.</strong></p><ul><li><strong>SSRIs versus placebo:</strong><ul><li>Evidence is based on a Cochrane review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Soomro et al, 2008</a>] and another systematic review commissioned by the National Institute for Health and Clinical Excellence (NICE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>]. There were differences between the reviews in terms of the studies included, despite no new studies being published in the interim: NICE included six studies not found or included in the Cochrane review, and, conversely, the Cochrane review included five studies not included by NICE. However, the results were broadly similar.</li><li>Both systematic reviews found a statistically significant difference favouring SSRIs over placebo in achieving clinical (treatment) response (as defined by 25% or 35% reduction in Yale-Brown Obsessive-Compulsive Scale [Y-BOCS] score):<ul><li>Relative risk (RR) 1.84, 95% CI 1.56 to 2.17 (13 studies; n = 2697) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Soomro et al, 2008</a>].</li><li>RR 0.77, 95% CI 0.73 to 0.82 (10 studies; n = 2588) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>].</li></ul></li><li>Both systematic reviews found SSRIs to be superior to placebo in reducing obsessive-compulsive disorder (OCD) symptoms as measured by clinician-rated Y-BOCS:<ul><li>Weighted mean difference (WMD) –3.21, 95% CI –3.84 to –2.57 (17 studies; n = 3097) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Soomro et al, 2008</a>].</li><li>Standardized mean difference (SMD) –0.42, 95% CI –0.53 to –0.31 (12 studies; n = 1629) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>].</li></ul></li><li>SSRIs were associated with an increased risk of adverse effects (most commonly nausea, headache, and insomnia) (RR 1.16, 95% CI 1.1 to 1.23) but no statistically significant difference in withdrawals, leading to the conclusion that SSRIs are relatively well tolerated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>].</li><li>Continuation of SSRIs appears to be significantly more effective than placebo for up to 48 weeks, and long-term treatment up to 12 months appears to prevent relapse [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>].</li></ul></li><li><strong>Different doses of SSRIs:</strong><ul><li>There is limited evidence from a systematic review commissioned by NICE that higher doses are superior to lower doses for citalopram, fluoxetine, and paroxetine and that higher doses may be associated with a lower risk of withdrawals [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>].</li></ul></li><li><strong>SSRIs versus other SSRIs:</strong><ul><li>Evidence is based on a systematic review commissioned by NICE and appraisal of one of the original studies from that review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Mundo et al, 1997</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>].</li><li>There is limited evidence suggesting a difference favouring sertraline over fluoxetine for reducing obsessive-compulsive symptoms as measured by the clinician-rated Y-BOCS (n = 148; SMD 0.39, 95% CI 0.07 to 0.72).</li><li>NICE states that 'there is limited evidence suggesting a difference favouring fluvoxamine over citalopram on reducing obsessive-compulsive symptoms as measured by the National Institute of Mental Health Obsessive-Compulsive Global Scale (NIMH-OC) (n = 21)'. However, the reported results appear to be incorrect: SMD 21.22, 95% CI –2.17 to –0.27. In the original single-blind study, which randomized just 30 inpatients to fluvoxamine, citalopram, or paroxetine, the authors report no significant differences between the groups in terms of NIMH-OC and Y-BOCS total scores, although the statistical data were not presented [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Mundo et al, 1997</a>].</li><li>The evidence was inconclusive for any differences in tolerability.</li></ul></li><li><strong>SSRIs versus clomipramine:</strong><ul><li>Evidence is based on a systematic review commissioned by NICE [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">National Collaborating Centre for Mental Health, 2006</a>].</li><li>There is no statistically significant difference between SSRIs and clomipramine in either treatment response (n = 1019; RR 1.02, 95% CI 0.89 to 1.17) or OCD symptoms (Y-BOCS) (n = 739; SMD 0.14, 95% CI –0.01 to +0.29).</li><li>SSRIs may be better tolerated: when compared with SSRIs, clomipramine increased the risk of leaving the study early for any reason (n = 1139; RR 0.72, 95% CI 0.59 to 0.88) or due to adverse effects (n = 1095; RR 0.62, 95% CI 0.46 to 0.84).</li></ul></li><li><strong>Escitalopram versus placebo and paroxetine:</strong><ul><li>One double-blind, RCT (sponsored by the manufacturer of escitalopram) found that escitalopram 20 mg daily is superior to placebo in reducing OCD symptoms as measured by clinician-rated Y-BOCS (mean difference –3.21, 95% CI –5.19 to –1.23; p<0.01, n = 228) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/obsessive-compulsive-disorder/references/\">Stein et al, 2007</a>]. However, escitalopram <em>10 mg </em>daily did not achieve statistical significance when compared in efficacy with placebo (mean difference –1.97, 95% CI –3.97 to +0.02; p = 0.052, n = 227).</li><li>It was not possible to conclude how escitalopram compares with paroxetine 40 mg daily owing to the absence of any useful statistical tests for differences in efficacy and tolerability.</li></ul></li></ul><!-- end field 0c8be71b-97bb-4133-bb7b-35ce26468a92 --><!-- end item e4873610-d04e-499c-85c8-d95dee5babe9 -->","topic":{"id":"1f37cc0e-7573-58d0-a414-18973c123eae","topicId":"394f419d-3ab3-4fd3-85c7-7ae0c286d323","topicName":"Obsessive-compulsive disorder","slug":"obsessive-compulsive-disorder","lastRevised":"Last revised in June 2018","chapters":[{"id":"6854ef67-5e05-528c-afeb-b7680f464892","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0151ee13-83cc-5d06-9ce4-f03bc14a2d91","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a6ac8f0f-9ef4-5778-82e7-0ee23afbaaf8","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f571042f-c058-5f39-a22d-6901a3f9f4d0","slug":"changes","fullItemName":"Changes"},{"id":"31a9215e-18d0-5bd1-9341-846c7185dd16","slug":"update","fullItemName":"Update"}]},{"id":"39a21515-e7bc-515d-80d4-420f429a801f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9c01874c-054d-55f7-bc72-c5dc572bb4ce","slug":"goals","fullItemName":"Goals"},{"id":"bb1af94d-3d5a-5862-9e75-51cfd39e9e31","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"31dd33b1-cd86-57bc-84c1-206363cae677","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8aa2028a-8646-59f5-ac0b-c585d5f9474a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"96f32bee-6f1f-5862-8163-8f9adf02e81e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0c41f244-6591-5043-825b-f48000a19060","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"69296d43-e92e-51ad-803f-9b00dd4ef3eb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"23304d59-7975-500a-9672-1d71c224d42b","slug":"definition","fullItemName":"Definition"},{"id":"75facf2a-3aa9-52ec-a213-c09d7c49305a","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ef703cf4-f71d-53e8-ac6e-55fd3949af89","slug":"prevalence","fullItemName":"Prevalence"},{"id":"16615ebe-7c11-54ea-8c8f-11b27bd84df0","slug":"prognosis","fullItemName":"Prognosis"},{"id":"9c3a46c7-846c-5e14-9297-e80dfc82ffa5","slug":"complications","fullItemName":"Complications"}]},{"id":"9063127c-d315-5f06-81a4-0854a79730a5","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8e2a1f2f-09ef-5f73-a3ec-2aac2b0a90b7","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"d07d5382-3d58-534c-80b0-ebb514c9d790","fullItemName":"Management","slug":"management","subChapters":[{"id":"adfa1e25-924b-5e4d-b909-bbd62bfa3981","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"1a83f73e-9ca7-5f30-9cda-aaa563048a36","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0b63ad08-27a9-5af8-8fb8-6940aa3d3dc3","slug":"ssris","fullItemName":"SSRIs"},{"id":"32401b30-535f-57bf-8154-4e5efa0884e3","slug":"clomipramine","fullItemName":"Clomipramine"}]},{"id":"34094942-974d-50ae-b83e-52a2243c1e47","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"06ebd4e9-a6ff-5645-8bf1-4a06d03e073b","slug":"psychological-treatments-in-adults","fullItemName":"Psychological treatments in adults"},{"id":"73a36a4c-8f66-5d63-a4ad-c1667bd42f3b","slug":"ssris-in-adults","fullItemName":"SSRIs in adults"},{"id":"f077f54e-c77f-533b-84b3-6f81c9eb4f89","slug":"pharmacological-versus-psychological-treatments-in-adults","fullItemName":"Pharmacological versus psychological treatments in adults"},{"id":"d63bb159-7b2d-54b3-a251-0fb81b09618f","slug":"combination-treatments-in-adults","fullItemName":"Combination treatments in adults"}]},{"id":"ed477751-4d36-5e3b-bfcb-60739e1daea7","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6e26607d-6208-5c71-a5ee-ba2bd8567311","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"700ff2f4-6d6b-5235-8301-91ad6701f206","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"20682403-8c70-5f97-86c4-1f8234b42261","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"9242ca74-0efb-54f8-9cb4-267acc46dc6c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"8a264e61-1997-5859-8b1d-e1d859ffa219","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c91ccb0b-b8e6-5c2a-ab14-79b9eff3e63a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"34094942-974d-50ae-b83e-52a2243c1e47","slug":"supporting-evidence","fullItemName":"Supporting evidence"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}